NEWS MAY 1, 2009

The FDA has issued a warning for both dieters and body builders today to immediately stop using Hydroxycut, a supplement linked to cases of serious liver damage and at least one death so far.

The FDA said the manufacturer of the popular dietary supplement has now agreed to recall 14 Hydroxycut products. Over 9 million packages were sold last year, the FDA said.

Dr. Linda Katz of the FDA’s food and nutrition division said the agency has received 23 reports of liver problems, including the death of a 19-year-old boy living in the Southwest.

Side effects and symptoms from Hydroxycut includes: jaundice, or yellowing of the skin, and even possible liver failure.

The FDA’s Dr. Katz said it has taken so long to get a handle on the Hydroxycut problem because the cases of liver damage were rare and the FDA has no authority to review supplements before they’re marketed. “Part of the problem is that the FDA looks at dietary supplements from a post-market perspective, and an isolated incident is often difficult to follow,” she said.

If you’ve been hurt or injured in any way from taking Hydroxycut, contact our lawyers and attorneys today as you may be entitled to compenstation for your Hydroxycut side effects injury.

For a free case review please visit this  Hydroxycut Injury Lawsuit website.

NEWS: April 22, 2009

If you or a loved one has been injured or has fallen ill due  to what you believe is a defective  drug product, do not delay in seeking immediate medical attention, as  prompt diagnosis and treatment may help to avoid irreparable damage.

It  is also important to take immediate legal action, as restrictive  statutes of limitations can prevent you from collecting the compensation you  are entitled.   Successful defective drug  litigation sends a clear message to the pharmaceutical industry about  accountability and consumer safety.

Below is a list of some of more dangerous drugs that have been mentioned in other websites.  Click on the links to find out more about these defective drugs or read about the different side effects.

Raptiva Lawsuits
Reglan Claims
Gadolinium Lawsuits Claim
Byetta lawsuit
Fentanyl Patch Injury Lawsuit
Yasmin Birth Control Injury Claim
NuvaRing Claim Lawyer
Avandia Attorney Lawsuits
Levaquin Lawsuit Attorney
Trasylol Injury Attorney

NEWS: April 16, 2009

A Calaxo bone screw is a product used for knee ACL reconstructive surgery and is smanufactured by Smith & Nephew, Inc.

On the market since 2006, Smith & Nephew spokesperson states, “Our Calaxo Osteoconductive Interference Screw is formulated with chemicals that stimulate the bone surface within the tunnel and trigger the development of new bone, which over time replaces the implant. It’s preferable to restore the bone tissue that has been removed to make way for the graft. CALAXO makes this possible.”

Calaxo Screw Problems and Side effects:

Swelling

Joint or knee pain

redness around the joint

Loss of flexability in the knee area

The Calaxo screw was recalled from the market in August 2007, after patients reported that they suffered swelling, fluid build-up around the knee, some had screw fragmentation bits and patients claimed pain in and around the knee. Other patients had to have some additional surgery to remove infected tissue, and removal of the screw fragments.

FDA Recall of the Calaxo Bone Screws

This is the FDA’s statement on the recall, “Post operative condition sterile fluid pocket has been identified, including the potential for graft failure and premature material degradation.”
If you or someone you know has suffered any related injury from a Calaxo Bone Screw device knee during surgery, contact a Calaxo Bone Screw lawyer today.

NEWS April 8, 2009 – Raptiva RECALL – The makers of the psoriasis drug Raptiva, Genentech Inc, has stated that they will pull the drug off the market. Raptiva has been recalled due to linked to an increased risk of progressive multifocal leukoencephalopathy (PML), a rare and usually fatal disease of the central nervous system.

Raptiva is approved for the treatment of chronic moderate-to-severe plaque psoriasis in adults 18 years or older who are candidates for systemic therapy or light therapy.

Genentech Inc., said Raptiva will not be available after June 8 and estimated that around 2,000 U.S. patients may be receiving the drug for chronic plaque psoriasis.

If you or a loved one has been harmed or injured from Raptiva please contact a Raptiva Lawyer

http://www.resource4thepeople.com/defectivedrugs/raptiva.html

NEWS: March 10, 2009

The U.S. Consumer Product Safety Commission in conjunction with Maytag Incorporated based in Newton, Iowa has issued a voluntary recall on 1.6 million refrigerators including the following brand names:
Maytag, Jenn-Air, Amana, Admiral, Magic Chef, Performa by Maytag and Crosley

Reason for the Maytag Refrigerator Recall:  41 reports of relay ignition, 16 reports of property damage.

Possible electrical failure in the relay, this is the component that turns the compressor, and may overheat and cause a serious fire hazard.  

Side-by-side Refrigerator Models Recalled.

Serial numbers must end with: AA, AC, AE, AG, AJ, AL, AN, AP, AR, AT, AV, AX, CA, CC, CE, CG, CJ, CL, ZB, ZD, ZF, ZH, ZK, ZM, ZQ, ZS, ZU, ZW, ZY and ZZ, and model numbers beginning with ARS, CS, JC, JS, MS, MZ and PS.

Top-Freezer Refrigerator Models Recalled.

Serial numbers must end with: AA, AC, AE, AG, AJ, AL, AN, AP, AR, AT, AV, AX, ZK, ZM, ZQ, ZS, ZU, ZW, ZY and ZZ, and model numbers beginning with AT, CT, MT and PT.

These refrigerators were purchased in department and appliance stores and by homebuilders across the US from January 2001 through January 2004. They sold for between about $350 and $1600.

Bottom Freezer Refrigerator Models are NOT recalled. 

If you or someone you know suffered property damage, fire, or worse from this Maytag refrigerator recall please visit this web site for a free legal case evaluation.

For more information, consumers can call Maytag toll-free at (866) 533-9817, or visit the Web site http://www.repair.maytag.com/.

NEWS: March 03, 2009

Reglan and Tardive Dyskinesia FDA Warning:

Reglan, the generic name for metoclopramide, is used in many drugs, and the FDA has now stated that all metoclopramide containing drugs carry a “boxed warning” for these drugs.

Link found between the use of Reglan and Tardive Dyskinesia has been established.

Other information on Reglan:

You should not take Reglan if you are allergic to metoclopramide, or if you have bleeding or blockage in your stomach or intestines, epilepsy or other seizure disorder, or an adrenal gland tumor (pheochromocytoma).
Before taking Reglan, tell your doctor if you have kidney or liver disease, congestive heart failure, diabetes, or a history of depression.

If you or a loved one has been diagnosed with Tardive Dyskinesia from Reglan use contact a Reglan Lawyer today

NEWS: 2/27/2009 FDA Warning for metoclopramide Reglan Tablets

FDA notified healthcare professionals that manufacturers of metoclopramide, a drug used to treat gastrointestinal disorders, must add a boxed warning to their drug labels about the risk of its long-term or high-dose use. Chronic use of metoclopramide has been linked to tardive dyskinesia, which may include involuntary and repetitive movements of the body, even after the drugs are no longer taken. These symptoms are rarely reversible and there is no known treatment. Metoclopramide is available in a variety of formulations including tablets, syrups and injections.
Names of metoclopramide-containing products include Reglan Tablets, Reglan Oral Disintegrating Tablets, Metoclopramide Oral Solution, and Reglan Injection. Manufacturers will be required to implement a risk evaluation and mitigation strategy [REMS] to ensure patients are provided with a medication guide that discusses this risk. Current product labeling warns of the risk of tardive dyskinesia with c hronic metoclopramide treatment.
Read the MedWatch 2009 safety summary, including a link to the FDA News Release, at:
http://www.fda.gov/medwatch/safety/2009/safety09.htm#Metoclopramide

Reglan side effects:

Seek medical help as soon as possible if you have any of these signs of an allergic reaction to Reglan or other metoclopramide products: hives; difficulty breathing; swelling in the face, lips, tongue, or throat area.

Stop using Reglan other metoclopramide products and call your doctor at once if you have any of these serious side effects or indications of tardive dyskinesia:

Restless muscle movements in either the eyes, your tongue, jaw, or neck; tremors.

Appearance of the face being “mask-like”.

Uneven heartbeats, rapid breathing, fever, stiff muscles, confusion or sweating.

Thoughts of suicide or hurting yourself or a overall depressed mood.

Hallucinations, anxiety, agitation, jittery feeling, trouble staying still.

Jaundice – yellowing of your skin or eyes.

Seizure and or convulsions.

If you’ve been hurt or injured from taking either Reglan Tablets or any other  metoclopramide based drug – fill out this form for a free case review.

NEWS: 2/26/2009

Raptiva linked to progressive multifocal leukoencephalopathy, also known as PLM is a side effect of this psoriasis drug. Other know Raptiva side effects include: Brain Infection, and  Progressive Brain Disease.

What is PML? (Progressive Multifocal Leukoencephalopathy)

PML is a rare brain infection that tends to affect patients whose immune systems are in a weakened state.  In fact, the active virus associated with PML, Polyomavirus JC, or the JC virus, is carried and present in most people, but those with healthy immune systems are never affected by it.  However, this is not apparently the case with those who have used Raptiva.

What’s even more problematic is that the symptoms of PML can be very diverse, making a clear diagnosis difficult.  The reason for this difficulty is that the JC virus causes a loss of white matter known as myelin in the brain that affects several areas where the needed protection offered by myelin is no longer present.

If injured from Raptiva please visit this website to contact a Raptiva Lawyer Today. 

Other facts on Raptiva can be found at this Raptiva and PML information web site.

This Raptiva and PML information was updated on 2/26/2009.

NEWS: February 19, 2009  FDA ALERT FOR RAPTIVA:

FDA has just issued a Public Health Advisory to notify healthcare professionals of three confirmed, and one possible report of progressive multifocal leukoencephalopathy (PML), a rare brain infection, in patients using the psoriasis drug Raptiva.

In October 2008, the labeling for Raptiva was changed to highlight, in a Boxed Warning, the risks of life-threatening infections, including PML. In addition, FDA directed Genentech, the manufacturer of Raptiva, to develop a Risk Evaluation and Mitigation Strategy, or REMS, to ensure that patients receive risk information about Raptiva.
The FDA is reviewing this latest information. The agency will take appropriate steps to ensure that the risks of Raptiva do not outweigh its benefits, that patients prescribed Raptiva are clearly informed of the signs and symptoms of PML, and that health care professionals carefully monitor patients for the possible development of PML. The Public Health Advisory provides recommendations for h ealthcare providers and patients when treatment with this product is considered.

Read the MedWatch safety summary, including links to the Public Health Advisory and News Release, at:
http://www.fda.gov/medwatch/safety/2009/safety09.htm#Raptiva

October 24, 2008

Raptiva is a drug that’s given to help treat psoriasis, and it’s generally given once per week to patients. It’s administered via an injection, and its main function is to suppress the patient’s immune system somewhat in order to alleviate the symptoms of their existing psoriasis. It’s generally been viewed in a positive light in terms of its results, but recent reports have prompted the FDA to issue the statement at issue here.
Raptive Side Effect Problems

Reports have surfaced in which patients have complained of the following side effects and symptoms while using Raptiva:

* Fever or chills
* Sore throat
* Coughing
* Congestion or other signs of infection
* Redness, pain, or swelling of a skin wound
* Burning or difficult urination

FDA Warning for Raptiva.

These symptoms have been found to potentially lead Raptiva users to develop the following conditions as a result of using this medication:

* Bacterial sepsis
* Viral meningitis
* Invasive fungal disease
* Progressive multifocal leukoencephalopathy (PML)

Specifically, one report seems to have prompted the FDA into action. It was the case of a 70-year-old man who had been using Raptiva for four years, or almost since the date it was originally approved for use. He developed a case of PML, which is a viral condition that attacks the brain progressively, and he ultimately was killed as a result.

In reaction to these reports, the FDA has recently issued a public alert that’s designed to help provide notice to medical professionals and the public at large. In furtherance of this notice, the FDA will now require a warning label to be affixed to every container of Raptiva that warns of the potential for these side effects.

For Raptiva Lawsuit information please visit this website Raptiva Lawyer

NEWS: January 8, 2009.

New 2009 California DUI laws & San Diego DUI Lawyer Information

New California DUI laws have now gone into effect starting January 1, 2009.

The new DUI laws include a new Zero Tolerance Law and Ignition Interlock Device Law.

Driving Under the Influence (DUI) Zero Tolerance (AB 1165, Maze) This new law prohibits a convicted DUI offender from operating a motor vehicle with a blood alcohol level (BAC) of .01 percent or greater while on probation for DUI. The law requires the driver to submit to a Preliminary Alcohol Screening (PAS) test, a portable breath test to determine the presence of alcohol. If the driver refuses, or if the driver submits and has a BAC of .01 or greater, a citation will be issued, the driver’s license will be taken and driving privileges will be suspended. In addition, the vehicle will be impounded.

Ignition Interlock Devices (IID) (SB 1190, Oropeza) This new law reduces the BAC from .20 percent to .15 percent or more at the time of arrest to trigger a requirement for the court to give heightened consideration for the installation of an IID for a first-time offender convicted of DUI of an alcoholic beverage.

Ignition Interlock Devices (SB 1388, Torlakson) Effective July 2009, this new law transfers authority for the administration of mandatory IID programs from the state courts to the Department of Motor Vehicles (DMV). This law also authorizes the DMV to require any driver convicted of driving with a suspended license due to a prior conviction for DUI to install an IID in any vehicle that the offender owns or operates.

Alcohol-Related Reckless Driving (AB 2802, Houston) This new law requires the court to order a person convicted of alcohol-related reckless driving to participate in a licensed DUI program for at least nine months, if that person has a prior conviction for alcohol-related reckless driving or DUI within ten years. Additionally, the court is required to revoke the person’s probation for the failure to enroll in, participate in, or complete a licensed DUI program.

 If you were arrested for a DUI please visit this San Diego DUI Lawyer website.